Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares
August 19 2024 - 2:21AM
Burning Rock Biotech Limited (the “Company” or “Burning Rock”)
announces that, on August 19, 2024, it intends to submit requests
(a) to the London Stock Exchange (the “LSE”), to cancel the
admission to trading on the Main Market of its American Depositary
Shares representing the class A ordinary shares of the Company (the
“ADSs”), and (b) to the UK Financial Conduct Authority, to cancel
the listing of the ADSs on the Official List.
As a result of sustained low volume of trading
and liquidity in the ADSs on the LSE, and taking into account the
costs associated with maintaining such listing in place, the
Company is seeking the delisting and cancellation of admission to
trading of the ADSs from the LSE (the “Delisting”). It is
anticipated that the Delisting will take effect on or about
September 18, 2024.
Following the Delisting, the ADSs will continue
to trade on the Nasdaq Global Market.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR and
LSE: BNR), whose mission is to Guard Life via Science, focuses on
the application of next generation sequencing (NGS) technology in
the field of precision oncology. Its business consists of i)
NGS-based therapy selection testing for late-stage cancer patients,
and ii) NGS-based cancer early detection, which has moved beyond
proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit:
www.brbiotech.com.
Contact: IR@brbiotech.com
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Aug 2023 to Aug 2024